EUVIMEDEUVIMED entdecken
Crossref

Thiotepa and Busulfan Combined With Cyclophosphamide Conditioning Regimen Plus Maintenance Therapy Improved the Disease‐Free Survival of Patients With Relapsed/Refractory Hematologic Malignancies After Undergoing Allogeneic Transplantation

Shulian Chen, Rui Cui iD, Yi He, Qiaoling Ma, Rongli Zhang, Xin Chen, Wenbin Cao, Jialin Wei, Donglin Yang, Aiming Pang, Sizhou Feng, Mingzhe Han und 2 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Shulian Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, the CAMS Innovation Fund for Medical Sciences, CIFMS, Tianjin Health Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conditioning regimens are critical for patients with relapsed/refractory (R/R) malignant hematologic diseases. Thiotepa, an alkylating agent with excellent cytotoxicity and blood‒brain barrier permeability, has been widely used in conditioning regimens for lymphoma and has recently been used in patients with acute leukemia with central nervous system involvement. The aim of this retrospective study was to observe the efficacy and safety of a conditioning regimen comprising thiotepa, busulfan, and cyclophosphamide (TBC) for allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in patients with R/R hematologic diseases. Between July 2022 and December 2023, 27 patients were selected. With a median follow‐up of 609 (243–954) days, the 1‐year and estimated 2‐year overall survival (OS) rates were 85.2% ± 6.8% and 76.5% ± 8.5%, respectively. The 1‐year and estimated 2‐year disease‐free survival (DFS) rates were 81.5% ± 7.5% and 62.8% ± 12.2%, respectively. Six patients experienced relapse, and the 1‐year and estimated 2‐year cumulative incidence of relapse (CIR) rates were 14.8% ± 6.8% and 31.0% ± 12.6%, respectively. Two patients died from graft‐versus‐host disease (GVHD) or infection. The 1‐year and estimated 2‐year nonrelapse mortality (NRM) rates were 4.2% ± 4.1% and 8.5% ± 5.8%, respectively. 14 (51.9%) patients received maintenance therapy after allo‐HSCT. Regimen‐related toxicities were mostly well tolerated. Multivariate analysis revealed that failure to achieve first complete remission (CR1) before HSCT and previous treatment with CAR‐T cell were predictors of poor DFS. This study suggests that the TBC conditioning regimen may be a promising option for patients with R/R hematologic diseases undergoing allo‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation ConditioningHematopoietic Stem Cell TransplantationHematologic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansBusulfanThiotepaFemaleMaleCyclophosphamideAdultMiddle AgedRetrospective StudiesTransplantation, HomologousYoung AdultAdolescentAgedDisease-Free SurvivalSurvival RateMaintenance ChemotherapyFollow-Up Studies

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationconditioning regimenrelapsed/refractory hematologic diseasesthiotepa and busulfan‐based

Substanzen

BusulfanThiotepaCyclophosphamide

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
  • College of Tianjin Medical University, Tianjin, China.

ORCID-Profile: Rui Cui

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • the CAMS Innovation Fund for Medical Sciences, CIFMS
  • Tianjin Health Research Project

Zitieren

APA

Chen, S., Cui, R., He, Y., Ma, Q., Zhang, R., Chen, X., Cao, W., Wei, J., Yang, D., Pang, A., Feng, S., Han, M., Zhai, W., & Jiang, E. (2026). Thiotepa and Busulfan Combined With Cyclophosphamide Conditioning Regimen Plus Maintenance Therapy Improved the Disease‐Free Survival of Patients With Relapsed/Refractory Hematologic Malignancies After Undergoing Allogeneic Transplantation. Hematological Oncology. https://doi.org/10.1002/hon.70138

Vancouver

Chen S, Cui R, He Y, Ma Q, Zhang R, Chen X, et al. Thiotepa and Busulfan Combined With Cyclophosphamide Conditioning Regimen Plus Maintenance Therapy Improved the Disease‐Free Survival of Patients With Relapsed/Refractory Hematologic Malignancies After Undergoing Allogeneic Transplantation. Hematological Oncology. 2026. doi:10.1002/hon.70138

BibTeX
@article{Chen2026,
  author = {Chen, Shulian and Cui, Rui and He, Yi and Ma, Qiaoling and Zhang, Rongli and Chen, Xin and Cao, Wenbin and Wei, Jialin and Yang, Donglin and Pang, Aiming and Feng, Sizhou and Han, Mingzhe and Zhai, Weihua and Jiang, Erlie},
  title = {Thiotepa and Busulfan Combined With Cyclophosphamide Conditioning Regimen Plus Maintenance Therapy Improved the Disease‐Free Survival of Patients With Relapsed/Refractory Hematologic Malignancies After Undergoing Allogeneic Transplantation},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70138}
}
Kostenlos starten →